Clinical Predictors of Good/Poor Response to Growth Hormone Treatment in Children with Idiopathic Short Stature
Authors' conclusion
We identified younger age and further distance from target HSDS as clinical predictors of response to GHT in a heterogenous population of children with ISS. Future studies, designed to identify the genetic determinants of response to GHT, could further facilitate individualisation of GHT.
Study context
- Population
- Prepubertal children with idiopathic short stature (ISS) on growth hormone (GH) treatment, aged 3–11 years (males) or 3–10 years (females) at startresponse analysis set
- Participants
- 207 children
- Comparison
- Good vs poor responders to GH treatment in year 1
- Primary endpoint
- Clinical characteristics predictive of good vs poor response to GH treatment
- Follow-up
- Year 1 of GHT
Methodological detailsNordiNet® IOS and ANSWER Program, logistic regression
- NordiNet® IOS and ANSWER Program
- Logistic regression
Primary result
As reported in the abstract
Independent predictors of good vs poor response · year 1
- Age at start of treatment: OR 0.69, 95% CI 0.5; 0.9, p = 0.0169
- Distance from target HSDS: OR 2.05, 95% CI 1.1; 3.9, p = 0.0259
Further findings
GH dose responsiveness
- Positive correlation between GH dose and change in HSDS
Original publication
Clinical Predictors of Good/Poor Response to Growth Hormone Treatment in Children with Idiopathic Short Stature. Horm Res Paediatr. Published 21 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →